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Abstract
In medicine, understanding the pathophysiologic basis of exceptional circumstances has led to an enhanced understanding
of biology. We have studied the circumstance of HIV-infected patients in whom antiretroviral therapy results in
immunologic benefit, despite virologic failure. In such patients, two protease mutations, I54V and V82A, occur more
frequently. Expressing HIV protease containing these mutations resulted in less cell death, caspase activation, and nuclear
fragmentation than wild type (WT) HIV protease or HIV protease containing other mutations. The impaired induction of cell
death was also associated with impaired cleavage of procaspase 8, a requisite event for HIV protease mediated cell death.
Primary CD4 T cells expressing I54V or V82A protease underwent less cell death than with WT or other mutant proteases.
Human T cells infected with HIV containing these mutations underwent less cell death and less Casp8p41 production than
WT or HIV containing other protease mutations, despite similar degrees of viral replication. The reductions in cell death
occurred both within infected cells, as well as in uninfected bystander cells. These data indicate that single point mutations
within HIV protease which are selected in vivo can significantly impact the ability of HIV to kill CD4 T cells, while not
impacting viral replication. Therefore, HIV protease regulates both HIV replication as well as HIV induced T cell depletion,
the hallmark of HIV pathogenesis.
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Introduction
Prior to the development of effective treatments for HIV
infection, the overwhelming majority of HIV-infected patients
experienced an inexorable depletion of CD4 T cells, resulting first
in immunodeficiency, followed by development of one or more
AIDS defining illnesses and then death. The advent of effective
therapies, and the knowledge of how best to use them, led to a
reversal of this pathway for a majority of patients. Following
initiation, the desired response to antiretroviral therapy is a
reduction in the level of viral replication, reflected by reduced
plasma viremia, and an increase in CD4 T cell number.
The study of exceptional circumstances has lead to some of the
most valuable advances in our understanding of HIV pathogen-
esis. For example, studying a subset of long term non-progressors
identified the CCR5D32 mutation as a factor in disease
progression, which in turn has lead to the development of
chemokine receptor antagonists as therapies for HIV infection.
Another exceptional circumstance in HIV infection is the situation
of immunologic response and virologic non response to antiret-
roviral treatment. Such discordance has been intensely studied and
found to occur in 10–20% of cases of patients initiating therapy
[1–3] and is more likely to occur in patients receiving a protease
inhibitor [3]. Immunologically, discordant patients have reduced
rates of apoptosis of CD4 T cells [4,5] and higher TREC content
[6], suggesting improved thymic function. Other quantitative
improvements in immune function have also been observed
relative to patients with both immunologic and virologic failure:
improved lymphoproliferative responses to recall antigens and
HIV antigens, improved cytokine production and improved IFNc
production [7–9]. Of importance, such responses can be
maintained for as long as five years [10], and are associated with
a reduced risk of disease progression [11] and death [12]
compared to non-responders. Despite few mechanistic studies
aimed at understanding such discordance, it is accepted that in the
presence of reduced drug susceptibility, a portion of benefit
achieved from therapy is due to persistent antiviral activity, as well
as reduced replicative capacity [13]. Of course this contention
requires that reduced replicative capacity translates into reduced
CD4 T cell losses, although this has never been specifically
demonstrated.
Expression of HIV-1 protease in cells is intrinsically cytotoxic
and this property was exploited to screen and develop the protease
inhibitor class, which has become an important treatment for
HIV-1 infected patients. Indeed, HIV protease has degenerate
substrate specificity and various host cellular proteins are targets
for HIV-1 protease which are then cleaved following HIV
infection including: actin, macroglobulin, myosin, spectrin,
vimentin, desmin, DNA fragmentation factors, filamin, eukaryotic
translation initiation factor-4c, fibronectin, microtubule–associat-
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in the cytoplasmic compartment of HIV-infected cells, the
cytotoxic effects are directly or indirectly related to cleavage of
one or more of these cellular proteins [15]. One substrate of HIV
protease is procaspase 8, and the absence of procaspase 8 renders
cells resistant to the cytotoxic effects of HIV protease [16].
Specifically at a molecular level, HIV protease cleaves procaspase
8 between two phenylalanine residues, F355 and F356, generating
a novel caspase 8 fragment of 41 kd that we call Casp8p41 [17].
Expression of Casp8p41 is independently cytotoxic and induces a
similar death pathway as HIV protease: mitochondrial depolar-
ization, release of cytochrome c, activation of caspases 9 and 3,
and DNA fragmentation [18]. Importantly, generation of
Casp8p41 occurs only following HIV infection or ectopic
expression of HIV protease and not following death induced by
other HIV proteins, death receptor signaling or mitochondrial
toxins [17]. Consequently, detecting Casp8p41 in cells from HIV-
infected patients [17] and the ability of Casp8p41 levels to predict
CD4 T cell losses [19], altogether suggests that HIV protease-
mediated killing occurs in vivo, and is of direct relevance to HIV
pathogens. Further, lymph nodes from HIV-infected patients with
detectable viral replication also express Casp8p41, which coloca-
lizes with both infected and apoptotic cells [20]. Altogether,
therefore, HIV protease production of Casp8p41 is one mecha-
nism by which HIV-infected T cells can die, that may contribute
to the overall CD4 T cell loss which occurs in vivo. In the current
study, we evaluated whether protease mutations which occur in
patients with discordant antiretroviral responses differ in their
ability to generate Casp8p41 and to cause cell death, compared to
patients with concordant antiretroviral responses.
Results
Resistance profiles of HIV protease differ between
patients with discordant versus concordant responses to
ART
In response to subinhibitory concentrations of protease
inhibitors, HIV protease resistance mutations are selected, which
often involve both primary active site mutations that directly
inhibit the action of PI, and a host of accessory resistance
mutations that may occur far from the active site but may
contribute to restoring the fitness or stability of protease activity
[21]. We sought to determine whether the prevalence of PI
mutations differed between patients with discordant virologic
failure versus age matched ART treatment matched patients with
concordant virologic failure. We used a strict definition of
discordant failure [22], that is consistent with other published
definitions [23] of increasing viral load over a period of three or
more months, coincident with an increase in CD4 T cell number
over the same timeframe in any patient receiving a combination of
three or more antiviral agents. We compared the prevalence of
mutations within protease of viral isolates from 34 patients with
discordant virologic failure and immunologic responses, to 34
patients with virologic failure that was associated with immuno-
logic decline. The clinical characteristics of these patients are
described in Table 1. The median (interquartile range) increase in
HIV viral load from the first measurement after initiating therapy
to the peak after failure was1.17 (0.47–2.04) log10 copies/mL. Our
rationale was that if protease mutations were unrelated to the
generation of a discordant response, then the frequency of
protease mutations should be similar between discordant patients
and those with concordant failures. Conversely, if specific protease
mutations predispose to the development of discordant response,
then those mutations should occur with a significantly higher
frequency in discordant compared to concordant virologic failures.
Indeed in discordant patients a high frequency of mutations in
protease were seen in selected sites that differed from that seen in
patients with concordant failures. Differences were significant for
mutations at amino acids 10 (p=0.03) 54 (p=0.001), and 82
(p=0.008) (Figure 1). We termed these mutations Discordance
Associated Mutations (DAMs).
Selected protease mutations impair protease mediated
cell killing
We next tested whether DAMs reduce the ability of HIV
protease to kill host cells relative to non-DAM mutations. For this
we chose the DAMs I54V, V82A, and the non-DAMs K20R,
L63P, D30N and L90M. A YFP-PR fusion construct was
developed containing the p6 and RT cleavage sites which
Author Summary
Although most patients infected with HIV who have
persistent viral replication will experience a decline in CD4
T cell number, this is not always the case. In a small subset
of patients in whom ART fails to suppress viral replication,
CD4 T cell counts do not fall, for unknown reasons. We
identified that these patients have an increased frequency
of selected protease mutations, which we call discordance
associated mutations (DAMs). While wild type protease
rapidly induces cell death, protease containing DAMs have
an impaired ability to induce cell death, due to a selective
defect in cleavage of caspase 8. Furthermore, viruses
containing DAMs replicate as efficiently as wild type, yet
fail to induce infected cell death. These results demon-
strate an unanticipated role of protease in determining the
immunologic outcome of HIV infection in vitro and in vivo.
Table 1. Demographics of discordant and concordant patients.
Discordant (N=34) Concordant (N=34)
Mean Age (range) 42.7 (24–58) 43.9 (26–55)
Sex (M:F) 34:0 32:2
Change in CD4 +76 (15 to 286) 2113 (222 to 2325)
Change in VL (log) +1.17 (0.4722.04) +1.03 (0.55–1.87)
Duration of detectable viremia (months) 9.2 (3 to 17) 8.1 (3 to 21)
# receiving a PI 34/34 34/34
Years diagnosed with HIV 6.1 (2–18) 5.2 (3–15)
doi:10.1371/journal.ppat.1001213.t001
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construct auto-processes to generate mature 11 kd protease
(Figure 2). Within this backbone, we introduced the point
mutations by site directed mutagenesis. In addition, we introduced
the control mutations of active site dead D25G, and T26S which
has been shown to have reduced protease catalytic and cytotoxic
activity [24].
We have previously shown that expression of HIV-1 PR causes
cell death which is associated with loss of mitochondrial
transmembrane potential, caspase 3 activation and nuclear
fragmentation [16]. After transfection with YFP and YFP
protease, He-La cells were assessed for loss of mitochondrial
transmembrane potential in the YFP-PR positive cells by TMRE
staining, which is a hydrophobic dye, taken up by mitochondria
with intact transmembrane potential. We specifically evaluated
TMRE loss in the YFP positive cells, indicating expression of
protease. Expression of YFP alone or YFP with catalytically
inactive YFP D25G PR resulted in minimal loss of transmembrane
potential. Conversely, YFP-WT PR or treatment with CCCP,
which uncouples mitochondrial transmembrane potential, resulted
in significant loss of TMRE retention (Figure 3A). Strikingly,
expression of YFP-L63P PR, YFP-D30N PR, YFP-K20R-PR, or
YFP-L90M PR caused high degrees of transmembrane potential
loss, similar to WT Protease. In contrast, YFP-PR fusions
containing the DAMs I54V, V82A caused a lesser degree of
transmembrane potential loss than WT-PR, that was similar to
that of catalytically impaired T26S (Figure 3B).
The putative impairment in cytotoxic activity of I54V and
V82A were next assessed by an independent measure of death,
generation of active caspase 3, and consequent caspase 3 activity.
Consistent with previous findings, WT protease expression
generated a significant amount of active caspase 3, and of caspase
3 activity (Figure 4A, 4B, 4C). Mirroring the results of TMRE
staining, I54V and V82A had reduced generation of active caspase
3 and caspase 3 activity than WT protease, while K20R, L63P,
D30N, L90M, generated similar levels of active caspase 3 and of
caspase 3 activity as WT (Figure 4A, 4B, 4C). TUNEL staining
confirmed these observations (Figure 5A, 5B) seen with TMRE
staining and caspase 3 activity assays; the DAMs I54V, and V82A
are associated with reduced induction of cell death compared to
WT or the non-DAMs L63P, D30N, L90M, or K20R.
In order to examine the relevance of these differences to
primary CD4 T cell death, we next transfected primary CD4 T
cells with the same constructs and analyzed death by TUNEL
positivity. YFP positive primary CD4 T cells containing I54V or
V82A protease had significantly fewer apoptotic cells than YFP
positive primary CD4 T cells containing WT, K20R, L63P, D30N
or L90M protease (Figure 6). Altogether, these data confirm the
underlying observation that the DAMs I54V and V82A cause less
cell death than either WT HIV PR, or the other non-DAM
mutants tested, confirming the reduced ability of protease
containing DAMs to kill infected cells.
HIV PR mutations that impair cell killing generate less
Casp8p41 in primary CD4 T cells
Our previous publications indicate that HIV PR mediated
killing requires procaspase 8 cleavage with subsequent generation
of Casp8p41 [16–18]. Therefore, if our model holds, the impaired
cell killing associated with I54V and V82A protease expression,
should be associated with less Casp8p41 production. To test this
Figure 1. Protease resistance mutations differ between patients with concordant and discordant virologic failure. Protease genotype
sequences were compared between 34 patients with concordant virologic failure, and 34 patients with discordant virologic failure, but immunologic
improvement. *Indicates p value ,0.05.
doi:10.1371/journal.ppat.1001213.g001
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CD4 T cells, and analyzed Casp8p41 production using a
neoepitope specific Casp8p41 antibody [17]. Whereas expression
of YFP WT protease in primary CD4 T cells resulted in a
significant proportion of Casp8p41 positive cells, expression of
either I54V or V82A resulted in significantly less Casp8p41
positivity than K20R, L63P, D30N, or L90M (Figure 7A, 7B).
In vitro cleavage of procaspase 8 vs. gag-pol sequences
by wild type or mutant PR
We next assessed the ability of HIV protease to cleave
procaspase 8 to produce Casp8p41. We also compared the ability
of these protease constructs to cleave procaspase 8 relative to their
ability to cleave gag-pol, in order to understand whether the
reduced Casp8p41 production was due to a selective inability of
protease to cleave that substrate, or a global reduction in catalytic
activity. Two different 12 amino acid peptides were constructed
reflecting the 12 amino acids surrounding the protease cleavage
sites within caspase 8 and gag-pol. These peptides were generated
containing fluorescence resonance energy transfer peptides; a
DABCYL fluorescence acceptor group at the N terminus, and a C
terminal EDANS fluorescence donor group. In this system, the
DABCYL group acts to quench the EDANS fluorophore. Upon
cleavage into two separate fragments by HIV-1 protease (at the
Phe-Phe in Casp8p41 or at the Tyr-Pro in gag-pol), the
fluorescence of EDANS is unrepressed and peptide cleavage is
monitored by increasing fluorescence emission.
We tested WT HIV protease or the following point mutations:
D25G (active site dead), T26S (catalytically impaired), D30N,
F53L, or L90M; or the DAMs I54V and V82A produced in E-coli.
Each protease preparation was reacted against either the
Casp8p41 substrate or the gag-pol substrate. Of interest, the two
mutations (I54V and V82A) that are over represented in the
discordant subjects had reduced cleavage of the Casp8p41
substrate compared to WT protease or D30N, F53L, or L90M,
suggesting that these mutations have a selective impairment in the
ability to generate Casp8p41, and therefore, an impairment in the
ability to induce Casp8p41-dependent death (Figure 8A). In order
to control for the amount of protease tested in these assays, a
separate series of experiments were performed. Equal amounts of
recombinant protease were used to cleave the Casp8p41 substrate
as the gag-pol substrate. These results were used to calculate a
ratio of Casp8p41 cleavage relative to gag-pol cleavage. Strikingly,
only the I54V and V82A DAM mutations produced a ratio of
Casp8p41:gag-pol cleavage that was significantly less than the
ratio that was produced by WT HIV protease. By contrast, D30N,
F53L, and L90M all produced Casp8p41:gag-pol cleavage ratios
greater than WT protease (Figure 8B).
Impact of DAMs on outcome of HIV infection
We have presented evidence that the DAM mutations I54V
and V82A, have an impaired ability to cleave procaspase 8
relative to gag-pol. This would predict that viruses containing the
mutations should have preserved viral replication, yet a selective
impairment in Casp8p41 production and reduced killing of HIV-
infected cells. Therefore, we performed HXB2 virus infections of
the human T cell lymphoblastoid line MT4, and measured cell
viability, Casp8p41 content, and apoptosis by TUNEL positivity
in the HIV-infected cells, as well as viral replication kinetics.
Infection of MT4 cells with WT HXB2 virus resulted in a time-
dependent decline in total cell viability, such that by Day 8 post-
infection total cell viability approaches 60%, whereas uninfected
control cell viability remained .95% (Figure 9A). Infection with
HXB2 containing the non-discordance associated mutation
L90M caused a similar degree of loss of total cell viability,
Figure 2. Subcloning HIV-1PR. HIV protease along with flanking regions within RT and P6 fused with YFP was cloned into a mammalian
expression vector (A). Following expression, protease autocatalyses and cleaves itself out of the fusion protein creating an 11 Kd protease protein.
This activity is absent in the D25G protease inactive construct, and is reduced in the T26S catalytically impaired construct (B).
doi:10.1371/journal.ppat.1001213.g002
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associated mutations I54V or V82A caused significantly less loss
of total cell viability. These differences in total cell viability
occurred despite similar levels of viral replication as reflected by
similar levels of P24 antigen present in the culture supernatants,
from the infections with the L90M, V82A, or I54V virus
infections (Figure 9B).
We next specifically analyzed cell death induced in HIV-
infected cells, as well as in uninfected bystander cells by co-staining
with TUNEL and P24 antigen, and comparing death in the
infected (p24 positive, Figure 9C) and uninfected (p24 negative,
Figure 9D) T cell subsets. Consistent with the premise that
mutations in HIV protease will reduce the ability of HIV protease
to kill infected cells, protease containing V82A or I54V induced
less apoptosis in infected cells than either WT or L90M
(Figure 10A). Of interest this trend was also observed in the
uninfected cells, with less uninfected cell killing being observed
with I54V, and a trend towards less death in the V82A protease
mutant (Figure 10B).
The measurements of total cell viability reflect cell death
induced by all proapoptotic factors present in HIV-infected cell
cultures, including Tat, Nef, Env, Fas ligand, TRAIL, Casp8p41,
and others. As our underlying premise is that alterations in
protease will impact Casp8p41 induced death, which we have
previously shown to occur only within the infected cell subset, we
specifically analyzed Casp8p41 content (Figure 10C). Casp8p41
content was greatest in HXB2 WT infected cells and in the L90M
non-DAM infected cells. Consistent with our in vitro data infection
with HIV containing the DAM mutations I54V or V82A resulted
in reduced generation of Casp8p41.
Figure 3. Discordance Associated Mutations (DAMs) within HIV-1PR alters the loss of mitochondrial transmembrane potential. YFP
HIV protease or the indicated protease point mutants were expressed in HeLa cells, and the YFP positive cells were analyzed for loss of mitochondrial
transmembrane potential (A, B). *Indicates p value #0.05. Data reflective of at least three independent replicates. Bars with solid color represent
controls, bars with angled hatching represent DAMs, and bars with horizontal hatching represent non-DAMs.
doi:10.1371/journal.ppat.1001213.g003
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indicated protease point mutants were expressed in HeLa cells, and the YFP positive cells were analyzed for percent active caspase 3 positive (A, B),
and total caspase 3 activity (C). *Indicates p value #0.05. Data reflective of at least three independent replicates. Bars with solid color represent
controls, bars with angled hatching represent DAMs, and bars with horizontal hatching represent non-DAMs.
doi:10.1371/journal.ppat.1001213.g004
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PLoS Pathogens | www.plospathogens.org 6 November 2010 | Volume 6 | Issue 11 | e1001213Figure 5. Discordance Associated Mutations (DAMs) within HIV-1PR alters the generation of TUNEL positivity. YFP HIV protease or the
indicated protease point mutants were expressed in HeLa cells, and the YFP positive cells were analyzed for TUNEL positivity (A, B). *Indicates p value
#0.05. Data reflective of at least three independent replicates. Bars with solid color represent controls, bars with angled hatching represent DAMs,
and bars with horizontal hatching represent non-DAMs.
doi:10.1371/journal.ppat.1001213.g005
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In the current study we have identified mutations within HIV
protease which occur with an increased frequency in patients who
manifest a discordant response to antiretroviral therapy, and have
evaluated whether those mutations within HIV PR alter the
generation of Casp8p41 and consequently the rate of Casp8p41
induced death. Those studies show that the mutations I54V and
V82A cause less procaspase 8 cleavage, less Casp8p41 production,
and impaired induction of cell death following isolated protease
expression or HIV infection. This manifests as a reduced
proportion of cell death in cells which are directly infected with
HIV as well as a reduced proportion of cell death in the bystander
(uninfected cell) population. Reasons for less cell death in the
uninfected cells are unclear, but might involve an altered cytokine
milieu which is associated with reduced priming of cells towards an
apoptosis susceptible phenotype. A possible pathway by which this
might occur is through HIV infected cells releasing paracrine
factors when they die, which promotes an activated or apoptosis
susceptible population of bystander cells. In such a scenario, when
infected cell death is reduced, bystander death would likely also be
reduced. Soluble factors which might contribute to such an effort
on bystander cells include mitochondrial DNA, which is
recognized by innate mechanisms as a damage associated
molecular pattern, which leads to activation, inflammation and
AICD [25]. This might explain why others have reported changes
in CD8 T cell activation in patients who develop PI mutations
with out significant changes in viral replication [26].
It has previously been suggested that Protease mutations might
impact the ability of HIV to kill CD4 T cells, through unknown
mechanisms [27,28]. Finding that certain isolated mutations
within protease result in an impaired ability of protease to cleave
procaspase 8, and induce cell death, coupled with knowledge that
multiple mutations within protease cooperatively impact viral
replicative fitness [29,30], suggests that multiple mutations within
protease will likely influence the ability of protease to induce cell
death in a cooperative manner. Indeed the combined effect of
mutations which impair protease cytotoxic effects (e.g., I54V and
V82A) along with other mutations that do not (e.g., L63P, L90M)
will need to be individually assessed. In this light it is of great
interest that I54V and V82A have evidence of having co-evolved;
possibly by virtue of cooperative selection due to low Casp8p41
production [31]. Similarly the effects of mutations not residing
within protease itself, but influencing protease processing (e.g.,
gag-pol cleavage site mutations) will require testing.
The mutation L10I is also of interest, in that it caused an
intermediate degree of procaspase 8 cleavage generating less
Casp8p41 than WT protease, but more than I54V and V82A
(data not shown). Furthermore, expression of L10I caused less
protease induced death than WT protease, more than I54V and
V82A, albeit neither difference reached significance. This
observation suggests that there are likely degrees of impairment
in cell death afforded by different mutations.
It is generally agreed that the proportion of infected CD4 T cells
[32,33] is insufficient to explain the magnitude of CD4 T cell loss
that is seen during HIV infection. Although this conclusion is
almost certainly correct, further lines of evidence suggest that the
proportion of infected CD4 T cells that die might be higher than
originally suggested. This belief stems from several lines of
reasoning. First, presuming the situation where the majority of
infected cells die, then nucleic acid-based techniques to identify
infected cells would predictably lead to underestimates. This is due
to recent knowledge that during the terminal stages of apoptosis,
DNA and RNA is fragmented and consequently TUNEL assays
become positive. During this period of time when DNA and RNA
are cleaved, assays which rely upon detection of large (.2 kb)
HIV specific sequences as means of identifying infected cells would
predictably cause false negative results. Second, early assays used
Figure 6. Expression of Discordance Associated Mutations (DAMs) in primary CD4 T cells alters generation of TUNEL positivity. The
same constructs were used to transfect primary CD4 T cells, and the YFP positive cells analyzed for TUNEL positivity. *Indicates p value #0.05. Data
reflective of at least three independent replicates. Bars with solid color represent controls, bars with angled hatching represent DAMs, and bars with
horizontal hatching represent non-DAMs.
doi:10.1371/journal.ppat.1001213.g006
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with anti-p24 antibodies consistently identified a significant
proportion of CD4 T cells as containing p24; in many cases 1 to
3% of CD4 T cells contained p24 [34–36]. Third, studies using
GFP reporter cell lines or GFP labeled virus [37,38] infected
primary resting CD4 T cells consistently indicate greater than
20% of target cells are infected by HIV in vitro; it seems very
unlikely, therefore, that well less than 0.1% of susceptible target
cells would be infected in vivo. Fourth, we have analyzed Casp8p41
content in cells from HIV-infected patients both within the
peripheral blood and lymphoid tissues, and have consistently
demonstrated as many at 1–3% of CD4 T cells in the peripheral
blood of HIV-infected patients containing HIV-specific marker
Casp8p41 [17]. Therefore, in our view, it is likely that a
proportion of CD4 T cells are infected in vivo and that some of
these die through Casp8p41-dependent mechanisms. The in vivo
role of infected cell killing is further supported by recent data
whereby HIV infects and kills CD4 T cells in vivo [39]. However, it
still remains unknown what the relative contribution of infected
cell killing to uninfected cell killing is in vivo. Data contained in the
current report suggests however that patients harboring selected
protease mutations might have a higher proportion of infected
cells that do not die through this Casp8p41 mechanism.
Identification of Casp8p41 as a mechanism by which infected,
but not uninfected, cells die following HIV infection, along with
the current observation that HIV PR resistance is associated with
impaired CD4 T cell killing, allows a potential explanation for
observations that arose during a period when PI drug resistance
Figure 7. Reduced HIV-1PR-induced cell death is associated with reduced Casp8p41 production. YFP HIV protease or the indicated
protease mutants were expressed in primary CD4 T cells and YFP positive cells were analyzed for Casp8p41 positivity (A, B). *Indicates p value #0.05.
Data reflective of at least three independent replicates. Bars with solid color represent controls, bars with angled hatching represent Discordance
Associated Mutations (DAMs), and bars with horizontal hatching represent non-DAMs.
doi:10.1371/journal.ppat.1001213.g007
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during that era consistently observed impaired CD4 T cell losses,
despite ongoing viral replication [40–42]. Demonstrating that
select protease inhibitor resistant mutations are associated with
impaired CD4 T cell killing and impaired Casp8p41 allows the
possibility that changes in Casp8p41 production might impact
CD4 T cell depletion. Future studies aimed at evaluating the
cooperative effects of multiple mutations within protease on
Casp8p41 production, along with longitudinal evaluations of
Casp8p41 as a predictor of CD4 T cell change should help answer
this question.
Materials and Methods
Patient samples
Patient genotypes were abstracted from the clinical records of
patients attending the immunodeficiency clinic of the University of
Ottawa. Patients were selected in 2002 based upon a rising viral
load over a period of three or more months while receiving three
or more antiretroviral agents. When CD4 counts rose over that
period, they were classified as discordant virologic failures, as we
have previously described [22]. When CD4 counts fell over that
time period they were classified as concordant virologic failures.
This protocol was reviewed and approved by the IRB of the
University of Ottawa. Written informed consent was waived as
samples were de-identified. All patients provided oral consent, as
required by the IRB, which was documented.
HXB2 HIV containing protease mutations
HIV (HXB2) viral stocks containing either the WT protease
gene or mutations coding for single amino acid substitutions (I54V,
V82A, or L90M) of the protease gene were produced as follows:
Mutant PR coding sequences were generated from a pGEM vector
containing the HIV-1 LAI (clone HXB2) PR and RT coding
sequence, using the QuikChange Site-Directed Mutagenesis Kit
(Stratagene, Foster City, CA) and high-performance liquid
chromatography-purified primers (Genset Oligos). Genotyping
of the HIV coding sequences in the plasmids upon site-directed
mutagenesis confirmed the presence of the desired change(s).
HXB2 proviral clone [43]. The presence of the desired mutation(s)
in the recombinant viruses was confirmed by genotyping. The
HIV-1 viral stocks were propagated by infecting MT4 cells. After
24 hours, infected MT4 cells were washed and resuspended with
complete RPMI. The cells were incubated and when cytopathic
effects occurred, the recombinant viruses were harvested and viral
concentration measured by p24 ELISA. HIV protease sequences
were verified by RT-PCR followed by DNA sequencing. Equal
amounts of virus as determined by p24 were stored at 280uCo r
used directly to infect primary CD4 cells.
Cell culture, transfection and Western blot
Primary CD4 T cells were harvested from peripheral blood, and
separated by negative selection using RosetteSep (Stem cell
technologies). Transfection of primary human Cd4 T cells was
accomplished using Amaxa Nucleofector. HeLa cells were
purchased from ATCC (Manassas, VA). Cells were maintained
in Dulbecco Modified Eagle Medium (DMEM) or RPMI1640
(GIBCO, Carlsbad, CA) supplemented with 10% (v/v) FBS, 1%
penicillin and streptomycin, and 2 mM L-glutamine, and
incubated at 37uC in a humidified atmosphere containing 5%
CO2. To transfect HeLa cells, exponentially growing cells were
transfected with DNA plasmids isolated from CsCl gradients and
delivered into cells with Fugene 6 at a ratio of 1 mg DNA: 2 ml
Fugene 6. For Western blot analysis, 50 mg of cytosolic proteins
were fractionated on a 15% polyacrylamide gel, then transferred
onto PVDF membrane (Millipore, Bedford, MA) for 3 hours at
1000 mA using transfer buffer (25 mM Tris, 192 mM glycine).
The membranes were blocked by incubation in TBS buffer
(20 mM Tris, 150 mM NaCl, 0.05% Tween, pH 7.5) containing
2% BSA overnight at 4uC and washed five times with TBS buffer.
Then the membranes were blotted for 1 hour at room
temperature with a primary antibody against HIV protease (AIDS
Reagent Program). The blots were washed five times with TBS
and developed with an HRP linked secondary antibody. The blot
was developed using SuperSignal (Pierce, Rockford, IL) following
the manufacturer’s protocol.
Plasmid construction and DNA sequencing
YFP-HIV-1 PR was constructed by inserting a PCR product
developed from the WT HxB2 provirus plasmid encompassing the
PR gene plus 69 base pairs upstream and 60 base pairs
downstream of the PR gene into the EcoRI/BamHI sites of
pEYFP-C1 (Clontech, Mountain View, CA). The PR sequence
was confirmed within the EYFP open reading frame by DNA
sequencing at Mayo Clinic’s Molecular Core Facility. The PR
mutants, L10I, K20R, D25G, T26S, D30N, I54V, L63P, V82A
and L90M were created on the pEYFP-C1PR plasmid with the
Quick-Exchange Site-directed Mutagenesis Kit (Stratagene, La
Jolla, CA). The primers used are as follows:
K20R sense: 59-GGGCAACTAAGGGAAGCTCTA-39, anti-
sense: 59-TAGAGCTTCCCTTAGTTGCCC-39; D25G sense:
59-AGGAAGCTCTATTAGGTACAGGAGCAGATGA-39, an-
ti-sense: 59-TCATCTGCTCCTGTACCTAATAGAGCTTCC-
T; T26S sense: 59-GAAGCTCTATTAGATAGTGGAGCA-
GATGATACA-39; anti-sense: 59-TGTATCATCTGCTCCAC-
TATCTAATAGAGCTTC-39; I54V sense: 59-GGAATTGGA-
GGTCTTATCAAAGTAAGA-3; anti-sense: 59-TCTTACTTT-
GATAAGACCTCCAATTCC-39; I54V sense: 59-ATTGGA-
GGTTTTGTCAAAGTAAGACAG-39, anti-sense: 59-CTGTC-
TTACTTTGACAAAACCTCCAAT-39; L63P sense: 59-GTAA-
GACAGTATGATCAGATACCCATAGAAATCTGTGGAC-
39; anti-sense: 59-GTCCACAGATTTCTATGGGTATCTGAT-
CATACTGTCTTAC-39; V82A sense: 59-GTAGGACCTA-
CACCTGCCAACATAATTGGAAG-39; anti-sense: CTTCCA-
ATTATGTTGGCAGGTGTAGGTCCTAC-39; L90M sense:
59-TAATTGGAAGAAATCTGATGACTCAGATTGGTTG-39;
and anti-sense: 59-CAACCAATCTGAGTCATCAGATTTCT-
TCCAATTA-39. All primer synthesis and mutation confirmation
was carried out in Mayo Clinic’s Molecular Core Facility.
Figure 8. Recombinant HIV protease containing Discordance Associated Mutations (DAMs) has an impaired ability to cleave
procaspase8 relative to gag-pol. HIV protease was produced in e.coli, and wild type protease, or the indicated point mutants were incubated
with a fluorogenic peptide corresponding to the site in procaspase8 which is cleaved by HIV protease, and cleavage monitored over time by
measuring fluorescence release (A). In order to normalize for the amount and activity of the protease preparations, HIV protease used above was also
analyzed for gag-pol cleavage by using a fluorogenic peptide corresponding to the gag-pol cleavage site. At each time point a ratio was calculated
by dividing the fluorescence released in the procaspase 8 cleavage assay with the amount of fluorescence released in the gag-pol cleavage assay. The
ratio is depicted in (B).
doi:10.1371/journal.ppat.1001213.g008
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PLoS Pathogens | www.plospathogens.org 11 November 2010 | Volume 6 | Issue 11 | e1001213Figure 9. HXB2 HIV containing Discordance Associated Mutations (DAMs) are associated with impaired killing of primary CD4 T
cells. Primary CD4 T cells were infected with HXB2 containing wild-type HIV protease, or protease containing the mutations L90M, I54V, or V82A, and
analyzed for (A) cell viability by ATP production, (B) P24 production, and (C) TUNEL positivity in the infected (P24 +), or (D) uninfected (P24-) subsets.
doi:10.1371/journal.ppat.1001213.g009
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PLoS Pathogens | www.plospathogens.org 12 November 2010 | Volume 6 | Issue 11 | e1001213Figure 10. HXB2 containing Discordance Associated Mutations (DAMs) are associated with reduced generation of TUNEL positivity
and reduced Casp8p41 production. Cells were infected as in Figure 9 and analyzed for TUNEL positivity in the P24 positive (A) or P21 negative (B)
cells, as well as for Casp8p41 (C). Results in (A) and (B) are pooled results from three independent experiments. Data in (C) is reflective of three
independent replicates.
doi:10.1371/journal.ppat.1001213.g010
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(MMP), TUNEL and Casp8p41 by flow cytometry
Mitochondrial membrane potential (MMP) of the YFP and YFP
fusion transfected cells was measured with the mitochondrial
specific red fluorescent dye, tetramethylrhodamine, ethyl ester,
perchlorate (TMRE) [44]. Briefly, 100 nM TMRE was added to
1610
6 cells in 1 ml PBS at 37uC for 20 minutes. TMRE and YFP
double positive cells were analyzed by flow cytometry at 20,000
events per sample. To measure apoptosis, the In Situ Cell Death
Detection kit (Roche Applied Science, Indianapolis, IN) was used
to stain 39 DNA strand breaks following the manufacturer’s
protocol. Briefly, CD4 T cells were fixed in 2% paraformaldehyde,
and permeabilized in 0.1% sodium citrate containing 0.1% Triton
X-100 for 5 minutes. Fixed cells were resuspended in 50 mlo f
TUNEL reaction buffer containing PE-dUTP and 5 U TdT, and
analyzed by flow cytometry. To determine the expression of
Casp8p41, 10‘6 peripheral blood lymphocytes were fixed with 2%
paraformaldehyde in PBS then permeabilized with PBS plus 0.1%
NP-40 on ice for 2 minutes and then incubated with Alexa 647- or
PE-labeled Casp8p41 antibody [17] for 1 hour. Flow cytometry
was performed using a FACScan (Becton Dickinson, Franklin
Lakes, NJ) and analyzed using CellQuest software.
Confocal microscopy
HeLa cells were seeded onto glass coverslips and transfected
with plasmids coding for YFP-HIV protease WT or mutants.
TUNEL staining for detection of apoptosis was done according to
the manufacturer’s protocol (Roche, Nutley, NJ). DAPI was added
to identify nuclei. Laser-scanning confocal microscopy was
performed using a Zeiss LSM-510 (Carl Zeiss Inc., Thornwood,
NY).
Caspase 3/7 activity detection
Caspase 3/7 activity in HIV-1 PR WT and mutant transfected
HeLa cells was measured with a Caspase 3 Fluorometric Assay Kit
(R&D Systems, Inc., Minneapolis, MN) following the manufac-
turer’s instructions. Briefly, the cells were harvested at 6–8 hours
after transfection, lysed, and equal amounts of protein were added
to each reaction in a 96 flat well microplate. The fluorescent
signals were read on a Microplate Fluorescent Reader (FL600,
Bio-Tek, Winooski, VT) using excitation and emission wave-
lengths of 340 and 450 nm, respectively.
HIV-1 protease activity assay
To assess the effect of the various mutations on the proteolytic
activity of HIV protease, a fluorometric assay was devised to
compare the relative rates of cleavage of a consensus gag-pol site
with the caspase 8 site. The fluorogenic peptides (gag-pol: Arg-
Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Lys(DABCYL)-
Arg; caspase 8: Arg-Glu(EDANS)-Pro-Lys-Val-Phe-Phe-Ile-Gln-
Ala-Lys(DABCYL)-Arg) were synthesized in the Mayo Protein
Core Facility such that fluorescence would be quenched until the
internal peptide is cleaved. Measurements were performed in 96-
well plates with a SPECTRAmax GeminiXPS spectrofluorometer
(Molecular Devices, Sunnyvale, CA). For each enzymatic reaction,
50 ml of cell lysates containing HIV protease was added to 150 ml
of protease assay buffer (0.1 M sodium acetate, 1.0 M sodium
chloride, 1.0 mM EDTA, 1.0 mM DTT, pH 4.7) containing
2.5 mM of either gag-pol or caspase 8 substrate peptide
prewarmed to 37uC. Fluorescence intensity readings at 490 nm
(excitation 340 nm) commenced immediately and data was
continuously recorded every 2 minutes for 60 minutes.
HIV-1 PR wild type or mutant protease expression
The PCR approaches were utilized to generate HIV-1 PR wild
type or mutant sequences from PR expression vector pEYEP-C1
using forward primer 59- AGAAGAGAGGATCCGATGT-
GGGGTAGA -39 and reverse primer 59- TTCTTC TGT-
GAATTCTCATTGTTTAAC - 39. The PCR product was
digested with BamH1 and EcoR1 (New England BioLabs,
Ipswich, MA), and ligated into the protein expression vector
pET-21b (EMD, Gibbstown, NJ) using T4 DNA ligase (Promega,
Madison, WI), which had been restriction digested with BamH1
and EcoR1. The ligation product was transformed into E-coli stain
BL21(DE3)pLysS (EMD, Gibbstown, NJ) cells. The insert was
confirmed by DNA sequencing, using dye terminator cycle
sequencing at Mayo DNA sequencing core facility. Proteases
were expressed by an induction of 1.0 mM isopropyl beta-D
thiogalactoside and bacterial pellet lysed directly using HIV-1 PR
assay buffer, in order to avoid protease degradation with
appropriate control cells lysate. The lysate were subjected to
protease assay, as described.
Statistical analysis
Values of continuous variables are expressed as means +/2
standard error. Comparisons of continuous variables were made
using T tests. The prevalence of resistance mutations in discordant
versus concordant patients was compared using the Fisher’s Exact
test. A P value of #0.05 was considered statistically significant.
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